English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Age related macular degeneration (AMD) and retinitis pigmentosa (RP) are two of the most common outer retinal degenerative diseases that have resulted in vision impairment and blindness of millions of people. Specifically, AMD has become the third leading cause of blindness on global scale, and is the primary cause of visual deficiency in industrialized countries (World Health Organization [WHO], 2011). In the United States, more than 500,000 people are suffering from RP and around 20,000 of them are legally blind (Artificial Retina Project, 2007). Whereas many treatment methods, including gene replacement therapy (Bennett et al., 1996), pharmaceutical therapy, nutritional therapy (Norton et al., 1993), photoreceptor and stem cell transplantations (MacLaren et al., 2006 & Tropepe et al., 2000), and dietary, have been explored to slow down the development of AMD and RP diseases in their early stages, vision impairment and blindness due to outer retinal degeneration currently remain incurable. In the 1990’s, researchers discovered that although the retinal photoreceptors are defective in RP patients, their optic nerves, bipolar and ganglion cells to which the photoreceptors synapse still function at a large rate (Humayun et al., 1999). Further studies showed similar results in AMD patients (Kim et al., 2002). These findings have created profound impact on the ophthalmology field, by providing the possibility of using artificial retinal prostheses to partially restore the lost vision function in AMD and RP patients. Two main retinal implant approaches are currently in development according to the layer of retina receiving the implanted device: subretinal (Chow et al., 2006; Rizzo, 2011; Zrenner et al., 1999) and epiretinal prostheses (Humayun et al., 1994; Weiland & Humayun 2008; Wong et al., 2009). Particularly, epiretinal implantation has received widespread attention over the last few years, for not only successful clinical trials demonstrating its efficacy in patients, but also its many advantages compared to others (Horch K.W. & Dhillon, G.S., 2004). First, the device implantation and follow-up examination only require standard ophthalmologic technologies, which can effectively reduce the risk of trauma during the surgery and also allow for the implant to be replaced easily. In addition, most of the implanted electronics are kept in the vitreous cavity so

Implantable Parylene MEMS RF Coil for Epiretinal Prostheses